**TYPE:** Case Report Publication

**TOPIC:** Transplantation

**INTRODUCTION:** Coronavirus disease 2019 (COVID-19) related severe acute respiratory distress syndrome (ARDS) cases have an extremely high mortality rate, even with the support of mechanical ventilation (MV) and extracorporeal membrane oxygenation (ECMO). This report provides initial experience of bilateral lung transplantation (LT) as a salvage therapy for patients with progressive deterioration of lung function and multiple negative nucleic acid tests post-COVID-19.

**CASE PRESENTATION:** A 58-year-old man had fever and cough for 1 day and a history of contact with a COVID-19 patient on January 20, presented to local hospital in Jiangsu Province, on January 23. COVID-19 was confirmed and progressively refractory hypoxemia was presented. MV support started from February 7 followed by tracheostomy. Convalescent plasma was infused. The patient still progressed to severe ARDS, although nucleic acid tests were negative. Veno-venous (V-V) ECMO was adopted to support the patient's life and LT was considered. On February 28, the patient manifested an unstable hemodynamic status and an urgent LT was performed with an additional V-A ECMO intraoperatively. ECMO was weaned off 37 hours post-surgery. The patient had intermittently weaned off MV since postoperative day 3 and the rehabilitation program was initiated.

**DISCUSSION:** This case inspires further consideration of candidate evaluation, protection of medical team and research on post-transplantation physical dynamics (Table 1). More evidence are needed to evaluate this salvage therapy in terms of the short-term and long-term benefits.

**CONCLUSIONS:** Although cases are limited, it provides initial experience on how to prepare both the medical team and the patient for the high-risk LT for ARDS post-COVID-19.
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